“We’ve got skin in the game“ – dedicated to global skin health! You have found what you are looking for: We are specialized in dermatology clinical research.

proinnovera is a dermatology specialized and owner-managed CRO (Clinical Research Organization) headquartered in Münster, Germany. We´re a full-service CRO, and we can conduct your clinical study from Phase II to IV in over 40 countries using our network of strategic alliances. more…

In addition to dermatology, we possess significant expertise in oncology and inflammatory diseases. You will benefit from this unique combination of therapeutic expertise, as well as from our experience from over 300 clinical studies conducted over the past 20 years. We know the nuances, challenges and tailor-made solutions for your dermatology, medical aesthetics, onco-dermatology or dermato-immunological clinical study. more…

Our goal is to deliver fast and efficient solutions for clinical research. It is our strong belief that this is the best way to make you successful and to make your product ready for the market.

Commitment, sustainability and success are the pillars of any cooperation. Giving our word and keeping our word is our guiding belief and creativity is our contribution!

 

Burkhard Breuer (CEO) & Marion Breuer (CEO) & Veronika Kunert (COO)

 

News and success stories

Proinnovera, specialty CRO for dermatology research, celebrates its 20th birthday this year

20 Years – “Infinite Passion for global Health”

Proinnovera celebrates its 20th birthday this year. Founded in 1997 as a 2-men company by Dr. Burkhard Breuer, we have grown to a mid-size and [...]

read more
News from the world of clinical research - proinnovera, CRO for dermatology, oncology and clinical research

Recruitment for Phase 3 Rescue Study closed 4 Months prior Milestone

In November 2016, proinnovera was awarded with the acquisition and conduct of a phase III rescue study in bacterial infected eczema by a mid-sized German [...]

proinnovera has successfully closed recruitment of a global Phase 2b study in mild to moderate Atopic Dermatitis 10 weeks ahead of schedule.

Recruitment closed ahead of schedule

proinnovera has successfully closed recruitment of a global Phase 2b study in mild to moderate Atopic Dermatitis 10 weeks ahead of schedule.

Jobs and Careers at proinnovera